Antineoplastics
1
Reactions 856 - 16 Jun 2001 S Antineoplastics Scleroderma: case report Scleroderma developed in a girl 9 months after she completed antineoplastic therapy for metastatic thymic carcinoma, which was diagnosed when she was aged 13 years. The girl’s treatment comprised 4 courses of vincristine 1.4 mg/m 2 on day 1, cisplatin 90 mg/m 2 on day 1, doxorubicin 30 mg/m 2 /day on days 1 and 2 and cyclophosphamide 10 mg/kg/day on days 1–3, repeated every 3 weeks. Maintenance therapy comprised cisplatin, dacarbazine, dactinomycin and cyclophosphamide [dosages not stated]. Antineoplastic therapy was stopped after 1 year as there was no tumour recurrence. Nine months later, she developed numbness of her hands and colour changes following exposure to cold temperatures. She had tight, shiny, atrophic skin over her face and limited movement of her finger muscles. There was dilatation of her oesophagus and decreased peristalsis, and mild restriction of her pulmonary function. Raynaud’s disease was also present. The girl was diagnosed with possible scleroderma and she was treated with oral methotrexate, but her attacks of Raynaud’s disease worsened. Her treatment was changed to penicillamine and prednisolone, but no improvement was seen during 14 months of follow-up. Author comment: ‘We strongly suspect that the immunomodulating drugs used in our case may have played a role in the development of the patient’s scleroderma.’ Emir S, et al. Scleroderma in a child after chemotherapy for cancer. Clinical and Experimental Rheumatology 19: 221-223, Mar-Apr 2001 - Turkey 800864470 1 Reactions 16 Jun 2001 No. 856 0114-9954/10/0856-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics
Reactions 856 - 16 Jun 2001
SAntineoplastics
Scleroderma: case reportScleroderma developed in a girl 9 months after she
completed antineoplastic therapy for metastatic thymiccarcinoma, which was diagnosed when she was aged 13 years.
The girl’s treatment comprised 4 courses of vincristine 1.4mg/m2 on day 1, cisplatin 90 mg/m2 on day 1, doxorubicin 30mg/m2/day on days 1 and 2 and cyclophosphamide 10mg/kg/day on days 1–3, repeated every 3 weeks. Maintenancetherapy comprised cisplatin, dacarbazine, dactinomycin andcyclophosphamide [dosages not stated]. Antineoplastictherapy was stopped after 1 year as there was no tumourrecurrence. Nine months later, she developed numbness ofher hands and colour changes following exposure to coldtemperatures. She had tight, shiny, atrophic skin over her faceand limited movement of her finger muscles. There wasdilatation of her oesophagus and decreased peristalsis, andmild restriction of her pulmonary function. Raynaud’s diseasewas also present.
The girl was diagnosed with possible scleroderma and shewas treated with oral methotrexate, but her attacks ofRaynaud’s disease worsened. Her treatment was changed topenicillamine and prednisolone, but no improvement wasseen during 14 months of follow-up.
Author comment: ‘We strongly suspect that theimmunomodulating drugs used in our case may have played arole in the development of the patient’s scleroderma.’Emir S, et al. Scleroderma in a child after chemotherapy for cancer. Clinical andExperimental Rheumatology 19: 221-223, Mar-Apr 2001 - Turkey 800864470
1
Reactions 16 Jun 2001 No. 8560114-9954/10/0856-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
